Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
Vicore Pharma announces that an application has been sent to the British medicines authority, MHRA to start a Phase IIa study with C21 in patients with Idiopathic Pulmonary Fibrosis (IPF). We are expecting feedback on the application within 60 days which is customary on applications to the MHRA.
“We have now reached an important milestone with the submitted application for the Phase IIa study. My colleagues have worked hard and dedicated with this submission. Now we await the evaluation of the application in cooperation with with our clinical partners” says Per Jansson, CEO Vicore Pharma.
For further information, please contact
Per Jansson, CEO
M: +46 709 17 47 46 or e-mail: email@example.com
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14.00 CET on December 22, 2017